RSS

protein therapeutics

Aprea Therapeutics, Karolinska Development’s portfolio company, has announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246. more

News

Integrating an Integra VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins. more

Technology